Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis
Open Access
- 4 November 2011
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 35 (1), 66-75
- https://doi.org/10.1111/j.1365-2036.2011.04912.x
Abstract
Aliment Pharmacol Ther 2012; 35: 66–75 Summary Background Thiazolidinediones (TZDs) have been used in the treatment of non‐alcoholic steatohepatitis (NASH). However, the magnitude of treatment response associated with TZDs in improving liver histology in NASH has not been quantified systematically. Aim To conduct a meta‐analysis of randomised, placebo‐controlled clinical trials (RPCTs) using pioglitazone and rosiglitazone in the treatment of NASH. Methods Pubmed/MEDLINE and Cochrane Central Register of Controlled Trials 2010 were searched until September 2010 and four RPCTs were identified. Peto odds ratios (ORs) and their respective 95% confidence intervals (CIs) were used to assess the efficacy of TZDs in improving liver histological parameters. Results Four good quality RPCTs derived from three continents were included. The meta‐analysis showed that TZDs (n = 169) were significantly better than placebo (n = 165) in improving ballooning degeneration, lobular inflammation and steatosis with combined ORs of 2.11 (95% CI, 1.33–3.36), 2.58 (95% CI, 1.68–3.97) and 3.39 (95% CI, 2.19–5.25) respectively. The improvement in combined necroinflammation with TZD (n = 58) vs. placebo (n = 52) was also statistically significant (combined OR 6.52[95% CI, 3.03–14.06]), but improvement in fibrosis was not. When pioglitazone (n = 137) was analysed alone, the improvement in fibrosis with pioglitazone (n = 137) vs. placebo (n = 134) (combined OR 1.68 [95% CI, 1.02–2.77]) was statistically significant. The total body fat slightly decreased in the control, while it markedly and highly significantly increased with TZD treatment. Conclusions Thiazolidinediones significantly improve ballooning degeneration, lobular inflammation, steatosis and combined necroinflammation in patients with NASH. Pioglitazone may improve fibrosis. Larger randomised, placebo‐controlled clinical trials are needed to examine the efficacy of thiazolidinediones in improving NASH fibrosis.Keywords
This publication has 34 references indexed in Scilit:
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical TrialsClinical Gastroenterology and Hepatology, 2008
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences, 2007
- Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990sCirculation, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneJournal of Hepatology, 2003
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneJournal of Hepatology, 2003
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severityGastroenterology, 1999